This presentation discusses CAR T-cell therapy for multiple myeloma. It explains what CAR T-cell therapy is, the process, and what clinical trials are indicating in regards to short- and long-term side effects, patient outcomes, and quality of life.

CAR T-cell therapy is a type of specialized immunotherapy that uses the patient's own modified T-cells to fight cancer. It is approved to treat certain blood cancers like lymphoma, leukemia, and multiple myeloma.

Multiple studies have shown that most patients who receive chimeric antigen receptor (CAR) T-cell therapy report a good quality of life long-term. Learn how CAR T-cell therapy is performed and its short-term and long-term effects on patients and caregivers. Discover key differences between CAR T-cell, stem cell transplant and other and chemotherapy treatments.

La terapia de Células CAR-T es una nueva terapia para pacientes con mieloma múltiple. Esta presentación explica qué es la terapia de Células CAR-T, cuál es su eficacia para los pacientes con mieloma y los posibles efectos secundarios.

CAR T-cell therapy is an exciting second-line option for patients living with relapsed multiple myeloma. In this presentation, Dr. Ahmed reviews each step in the CAR T process and discusses a number of studies that support its use. Potential side effects are reviewed, and exciting future trends are discussed.

CAR-T cell therapy is a promising new treatment for multiple myeloma. This presentation describes the versions of this therapy that are currently available, their potential complications and side effects, and the risk/benefit calculations in deciding when this treatment is appropriate.